Furthermore, the combinational treatment increased the MPL expression and stimulated the phosphorylation of JAK2, STAT3, and p38 MAPK in CML cells in vitro. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.